BACKGROUND.A new, total-immersion three-dimensional histoculture (TIH) method was developed to evaluate growth of tissue containing a mixture of benign prostate hyperplasia (BPH) and prostate cancer in vitro. METHODS. Efficacy of inhibitors, such as genistein, was determined by measuring 3 Hthymidine incorporation per microgram protein. Inhibitory effects obtained in TIH were compared to those in sponge-gel supported histoculture (SSH). RESULTS.3 H-thymidine incorporation was 2-5-fold higher in tissue cultured in TIH than in SSH. The average inhibition by genistein at a concentration of 18 M was 73% in TIH, vs. 31% in SSH. TIH also appeared to be more sensitive, since the lowest concentration of genistein that significantly inhibited growth of BPH mixed with prostate cancer tissue was 2.3 M, while in SSH the lowest concentration was 9.2 M. Although the within-assay coefficient of variation (CV) was similar for both TIH and SSH, the between-assay CV was better in TIH. CONCLUSIONS. These data suggest that TIH can be used as a discovery model for screening and evaluating inhibitors of prostate tissue growth in vitro.
that prostate disease is significantly less prevalent in Asia, where the intake of soy products is very high, than in the United States, where intake is low (Gu et al., 1994). We therefore undertook a study of the effects of genistein, a major component of soy, on growth of human-patient benign prostatic hyperplasia (BPH) and prostate cancer tissue in three-dimensional sponge-gel supported histoculture (SSH) (Hoffman, 1998). More recently, we improved the sensitivity of the histoculture method by the use of total immersion in the histoculture medium; we have called this technique total immersion histoculture (TIH) (Olbina et al, 1998).Surgical specimens of human BPH and cancer were histocultured with the SSH and TIH techniques in parallel for 5 days to study the effect of genistein on growth, as measured by inhibition of 3-H-thymidine incorporation per microgram of protein on day 5. RESULTS AND DISCUSSIONWe compared inhibition of growth after treatment of BPH and cancer tissue with genistein in SSH or TIH. Inhibition of growth was expressed as percentage of control growth of the tissue treated with dihydrotestosterone (DHT) alone. Incorporation of 3H-thymidine dramatically increased in control histocultures, by twofold to fivefold, in TIH compared with the same tissue in SSH (Fig. 1).We observed significantly increased growth inhibition of BPH and cancer tissue treated with 18.4 /xmol/L of genistein with TIH, compared with SSH. The average inhibition in TIH was 73% (range 67-79%), compared with a mean decrease of 31% (range 6-68%) in SSH (Fig. 2). This inhibition was statistically significant (P < .05).To examine the sensitivity of TIH, we treated BPH and cancer tissue in TIH with decreasing concentrations of genistein. We observed 40% growth inhibition of tissue treated with 4.6 /¿mol/L and 26% inhibition with 2.3 /¿mol/L, with a mean coefficient of variation (CV) of 13%. Both of these values represent significant differences (P < .05). In contrast, inhibition was not significant with concentrations lower than 9.2 ¿imol/L genistein in SSH (CV range, 8-29%) (Fig. 3).Inhibitory effects on 3H-thymidine incorporation of 20 ¿tmol/L of hydroxyflutamide, a known antiandrogen, were compared using the same tissue in SSH and TIH. In all experiments, the incorporation of 3H-thymidine was three to four times higher for TIH in control histocultures. The inhibition caused by 2 x 10-5 mol/L hydroxyflutamide was 40-60% in TIH. In SSH, inhibition by 2 X 10-5 mol/L hydroxyflutamide was 17-18%, and in some experiments it was not detectable to all.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.